ライフサイエンスコーパス: gemtuzumab ozogamicin

1 s predicted a greater or lesser benefit from gemtuzumab ozogamicin.

2 d by azacitidine, 75 mg/m(2) for 7 days, and gemtuzumab ozogamicin, 3 mg/m(2) on day 8, in older pati

3 ceive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intravenously).

4 less than 3.5 months after the last dose of gemtuzumab ozogamicin; 6 (40%) developed VOD.

5 ated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-ta

6 Liver injury developed in 11 patients after gemtuzumab ozogamicin administration; it was manifested

7 r patients benefit from the incorporation of gemtuzumab ozogamicin, an anti-CD33 mAb toxin, into indu

8 Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD3

9 t Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials

10 Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemoth

11 Gemtuzumab ozogamicin can be safely added to conventiona

12 ples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for P

13 Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoco

14 Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratorie

15 The addition of gemtuzumab ozogamicin did not increase the proportion of

16 out a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell

17 wed the course of 23 patients who were given gemtuzumab ozogamicin for AML that had relapsed after he

18 pt has been reinvigorated by the approval of gemtuzumab ozogamicin for treatment of acute myeloid leu

19 May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and

20 Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO anti-CD33 monoclonal antibody)

21 ated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in

22 ) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytot

23 Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibod

24 Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity a

25 Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults w

26 We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years

27 ndomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation

28 ated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients.

29 The encouraging results of gemtuzumab ozogamicin (GO) in newly diagnosed AML, and p

30 Gemtuzumab ozogamicin (GO) is a novel immunoconjugate th

31 Gemtuzumab ozogamicin (GO) is an immunoconjugate between

32 y Group (SWOG), which tested the addition of gemtuzumab ozogamicin (GO) to a 317 regimen in a randomi

33 val for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.

34 ted the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and pos

35 In 2000, gemtuzumab ozogamicin (GO) was granted accelerated appro

36 Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjug

37 Gemtuzumab ozogamicin (GO), a monoclonal antibody used i

38 (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33

39 Gemtuzumab ozogamicin (GO), an immunoconjugate of an ant

40 oid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO).

41 The antibody-targeted therapeutic, gemtuzumab ozogamicin (GO, Mylotarg), is approved for tr

42 n the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with ac

43 Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconj

44 While gemtuzumab ozogamicin (GTMZ) is commonly used in the tre

45 CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overal

46 In vitro gemtuzumab ozogamicin--induced apoptosis was also evalua

47 atic sinusoidal liver injury developed after gemtuzumab ozogamicin infusion.

48 ilure or sepsis at a median of 40 days after gemtuzumab ozogamicin infusion.

49 hat was sustained for at least 60 days after gemtuzumab ozogamicin infusion.

50 Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute

51 effective agents, such as purine analogs or gemtuzumab ozogamicin, is still under investigation, whe

52 eatment of acute myeloid leukemia (AML) with gemtuzumab ozogamicin may result in liver injury.

53 Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors,

54 Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells

55 momab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.

56 oconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically valida

57 e anthracycline, adding other agents such as gemtuzumab ozogamicin, or through 'timed sequential' the

58 isease, 19; refractory disease, 10) received gemtuzumab ozogamicin ranging from 6 to 9 mg/m2 per dose

59 However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined.

60 These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licen

61 However, the addition of gemtuzumab ozogamicin significantly reduced the risk of

62 tion of sinusoidal collagen, suggesting that gemtuzumab ozogamicin targets CD33(+) cells residing in

63 atient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult

64 However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD ch

65 Gemtuzumab ozogamicin was relatively well tolerated at 6

66 geting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an a

67 Gemtuzumab ozogamicin was the first example of antibody-

68 and suggest that treatment trials combining gemtuzumab ozogamicin with MDR reversal agents are warra

69 concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemother